Matchday Champions , a New Class of Mobile Football Game Now Available Worldwide; Kicks off With In-Game Event Hosted by Soccer Superstar Alexia Putellas and Mega Influencer Celine Dept
20.9.2024 14:00:00 EEST | Business Wire | Press release
Matchday, the developer of innovative mobile games for football’s five billion fans, has debuted its newest title, Matchday Champions. Today, the game is in early access globally, and it is celebrating with the limited-time “Copa Alexia x Céline,” a one-of-a-kind in-game tournament hosted by Spanish football World Cup Champion Alexia Putellas, and the immensely popular Belgian influencer Celine Dept.
Backed by Lionel Messi’s Play Time fund, Alexia Putellas, and other industry legends in sports and games, Matchday Champions is a one-of-its-kind experience. The game allows players to collect, craft and manage their own dream squad made up of both men's and women's players. It delivers the excitement of football using a cutting edge narrative creation engine, ensuring no two matches are ever the same. More than two million people have already pre-registered ahead of launch. Matchday Champions is now available in early access globally for iOS and Android phones.
Players who download the game can sign up to participate in the Copa Alexia x Céline, beginning on September 20. Hosted by World Cup champion, two-time Ballon d’Or winner and UEFA Women's Player of the Year Alexia Putellas and influencer Celine Dept, a football mega-fan with more than 50 million followers on YouTube, TikTok and Instagram, Copa Alexia x Céline challenges players to join Team Alexia or Team Celine, squaring off in a virtual tournament for bragging rights and prizes.
“Matchday is elevating two things I am very passionate about: women’s football and inclusivity,” said Putellas. “Women’s football has been on the rise for the last decade and Matchday’s co-gender football squads represent this reality in a fun and novel way for fans. I am honored to be a part of and shape a (virtual) football world that gives men and women truly equal footing. I hope the sort of representation we see in Matchday’s games will inspire the women’s football stars and all football fans of tomorrow, and help to drive forward conversations around equality.”
Licensed by FIFA and FIFPRO, Matchday offers fans the ability to collect digital player cards from tens of thousands of soccer athletes, and to combine both men’s and women’s players into their ideal squad to go head-to-head with other players’ teams. Players begin by assembling their squad, which they can start upgrading immediately. They then send their starting 11 onto the pitch, and Matchday Champions' proprietary simulation engine renders exciting in-game narratives. Play against rivals and friends while earning resources and recruiting footballers to improve their squad. Matchday Champions authentically captures the euphoria and heartbreak of real life football, and every match unfolds in a unique way.
“Football is an emotional experience for its five billion fans worldwide, and now they will be able to experience the drama of the sport in a video game that can seamlessly simulate games based on real players, real stats, and more,” said Sebastien de Halleux, Matchday co-founder and chief gaming officer. “Few players have experienced the emotional highs of football like Alexia Putellas, winning a World Cup, three UEFA Women's Champion Leagues, and 21 domestic trophies, along with all of her incredible individual accolades, so we’re honored that she has joined us not only as a Matchday ambassador but as the host of our first global in-game tournament.”
In Matchday Champions, players build and strengthen their squad, competing against others to move up through divisions and grow their club, competing with friends and Matchday’s vibrant global community, already numbering in the millions. Custom squads can be set up with ease through Matchday Champions' intuitive and accessible interface, allowing players to experiment with their team formation, as well as buy, sell and share cards with friends. Players hone their team in single player mode, then step on the pitch for a friendly match or an epic league competition with fans from all over the world. They can also join fans on the official Discord in discussing everything football, participate in weekly contests, participate in AMAs with football celebrities and follow real-world football matches.
Matchday continues to push the boundaries of digital ownership with Matchday Champions, which is part of a new category of sports games wherein fans build virtual squads by collecting digital cards of their favorite footballers. Players have true ownership of their cards and other digital items within Matchday Champions as they collect, trade and grow their dream team. These officially licensed cards can be utilized in all games within the Matchday ecosystem as it continues to grow.
Matchday previously launched the trivia and match prediction game Matchday Challenge: FIFA Women’s World Cup AU∙NZ∙2023™ Edition, which ran during FIFA Women’s World Cup and was played by millions of players all over the world.
Players can download Matchday Champions for free on the App Store or Google Play.
To learn more, please visit matchday.com, and join Matchday on X and Discord for the latest updates.
About Matchday
Matchday builds games for 5 billion football fans featuring officially licensed players and tournaments, in partnership with FIFA and FIFPRO. The company was founded by technology and gaming veterans who have successfully started and sold companies including Playfish (acq. EA), Glu Mobile (IPO), Hoodline (acq. Nextdoor), Spin (acq. Ford), and Viki (acq. Rakuten). Matchday is incubated by Leo Messi’s Play Time and backed by leading investors, with teams in San Francisco and Barcelona.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920697449/en/
Contacts
Sibel Sunar
fortyseven communications for Matchday
matchday@fortyseven.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom